KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Free Cash Flow: 2018-2025

Historic Free Cash Flow for Esperion Therapeutics (ESPR) over the last 8 years, with Sep 2025 value amounting to -$4.3 million.

  • Esperion Therapeutics' Free Cash Flow rose 87.92% to -$4.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$93.3 million, marking a year-over-year decrease of 257.77%. This contributed to the annual value of -$24.0 million for FY2024, which is 82.31% up from last year.
  • Latest data reveals that Esperion Therapeutics reported Free Cash Flow of -$4.3 million as of Q3 2025, which was up 86.36% from -$31.4 million recorded in Q2 2025.
  • Esperion Therapeutics' Free Cash Flow's 5-year high stood at $53.6 million during Q1 2024, with a 5-year trough of -$89.1 million in Q1 2021.
  • Moreover, its 3-year median value for Free Cash Flow was -$24.8 million (2023), whereas its average is -$19.8 million.
  • As far as peak fluctuations go, Esperion Therapeutics' Free Cash Flow skyrocketed by 198.67% in 2024, and later crashed by 337.82% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Free Cash Flow (Quarterly) stood at -$57.7 million in 2021, then grew by 26.40% to -$42.5 million in 2022, then increased by 12.75% to -$37.1 million in 2023, then rose by 5.68% to -$35.0 million in 2024, then soared by 87.92% to -$4.3 million in 2025.
  • Its Free Cash Flow stands at -$4.3 million for Q3 2025, versus -$31.4 million for Q2 2025 and -$22.6 million for Q1 2025.